https://www.rosehillreview.com 2026-10-01T19:07:54.577Z weekly 1 https://www.rosehillreview.com/blog 2026-10-01T19:07:54.577Z weekly 0.8 https://www.rosehillreview.com/archive 2026-10-01T19:07:54.577Z weekly 0.9 https://www.rosehillreview.com/issues/three-acquisitions-three-different-drugs-one-shared-bet 2026-09-25T00:00:00.000Z monthly 0.8 https://www.rosehillreview.com/issues/the-room-you-re-in-changes-what-psilocybin-does-to-your-brain 2026-09-18T00:00:00.000Z monthly 0.8 https://www.rosehillreview.com/issues/3-8b-the-largest-deal-this-field-has-seen 2026-09-11T00:00:00.000Z monthly 0.8 https://www.rosehillreview.com/issues/9-of-12-veterans-reach-remission-from-ptsd-in-new-trial 2026-09-04T00:00:00.000Z monthly 0.8 https://www.rosehillreview.com/issues/two-legal-paths-to-psilocybin-different-speeds 2026-08-28T00:00:00.000Z monthly 0.8 https://www.rosehillreview.com/issues/one-dose-one-month-of-new-brain-connections 2026-08-14T00:00:00.000Z monthly 0.8 https://www.rosehillreview.com/issues/the-first-safety-trial-built-for-ptsd-itself 2026-07-31T00:00:00.000Z monthly 0.8 https://www.rosehillreview.com/issues/two-phase-3-wins-what-the-evidence-now-establishes 2026-07-24T00:00:00.000Z monthly 0.8 https://www.rosehillreview.com/issues/how-far-is-psilocybin-from-becoming-a-covered-treatment 2026-07-07T00:00:00.000Z monthly 0.8 https://www.rosehillreview.com/issues/what-most-clinical-summaries-get-wrong-about-psilocybin-and-ptsd 2026-06-25T00:00:00.000Z monthly 0.8